Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous: 100 mg/mL) |
| Drug Class | Calcitonin gene-related peptide antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the preventive treatment of migraine in adults.
Summary
- Eptinezumab (Vyepti) is used for the preventive treatment of migraine in adults.
- A network meta-analysis of phase 3 randomized controlled trials showed that eptinezumab was associated with the lowest odds of treatment-emergent adverse events and serious adverse events compared to placebo, making it a safe and well-tolerated option for migraine prevention.
- In patients with chronic migraines, high doses of subcutaneous fremanezumab and intravenous eptinezumab were found to be effective therapies with acceptable safety and tolerability based on indirect comparisons from all outcomes analyzed.
- An integrated analysis across five large-scale clinical trials demonstrated that eptinezumab had a favorable safety profile, with most reported side effects being mild or moderate in severity; hypersensitivity reactions occurred in less than 2% of patients treated with this drug.
- The information provided is derived from nine systematic reviews/meta-analyses which included data pooled from multiple randomized controlled trials involving thousands of adult patients suffering from episodic or chronic migraines.
- Despite variations among studies regarding dosage levels and duration periods, overall findings consistently indicate that Eptinezumab offers significant benefits over placebo in reducing monthly migraine days while maintaining comparable rates of adverse events.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vyepti (eptinezumab-jjmr) Prescribing Information. | 2022 | Lundbeck Seattle BioPharmaceuticals Inc., Bothell, WA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. | 2022 | The Journal of Headache Pain |
| VA/DoD clinical practice guidelines: the primary care management of headache. | 2020 | U.S Department of Veteran Affairs |